Drug intelligence / Profile preview

Xanadu Bio HPV mRNA vaccine

Development stage: Preclinical
Lead developer: Xanadu Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

Xanadu Bio's HPV program is an mRNA-based therapeutic or prophylactic vaccine candidate currently in the discovery and preclinical stages. It utilizes the company's proprietary PACE (Polymer for Advancement of Cell Engineering) platform, which employs polymer nanoparticles to deliver mRNA specifically to mucosal epithelium. The program is designed to target Human Papillomavirus (HPV) to treat or prevent HPV-associated malignancies, specifically head and neck cancer and cervical cancer. The exact antigens or mRNA sequences have not been disclosed, but the approach focuses on tissue-specific delivery to mucosal surfaces.

Other names: HPV program

Beyond the preview

Go deeper on Xanadu Bio HPV mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xanadu Bio HPV mRNA vaccine.

Explore the full profile